Modality
ADC
MOA
VEGFi
Target
Menin
Pathway
STING
CLL
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
Jun 2021
→ Feb 2031
NDA/BLACurrent
NCT06664427
2,562 pts·CLL
2021-06→2026-01·Active
NCT04552456
1,967 pts·CLL
2021-12→2031-02·Recruiting
4,529 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-232mo agoPh3 Readout· CLL
2031-02-214.9y awayPh3 Readout· CLL
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Active
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-01-23 · 2mo ago
CLL
Ph3 Readout
2031-02-21 · 4.9y away
CLL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06664427 | NDA/BLA | CLL | Active | 2562 | EDSS |
| NCT04552456 | NDA/BLA | CLL | Recruiting | 1967 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |